{"url_path":"/sec/plx/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-18","source_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029858-index.html","accession_number":"0001104659-26-029858","cik":"0001006281","ticker":"PLX","issuer_name":"Protalix BioTherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029858-index.html","primary_entity_key":"0001006281","primary_entity_name":"Protalix BioTherapeutics, Inc."},"word_count":291,"has_tables":true,"body_markdown":"Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities\n\nMarket Information\n\nOur common stock is traded on the NYSE American under the symbol “PLX.” In 2023, we decided to voluntarily delist our common stock from the Tel Aviv Stock Exchange.\n\nHolders\n\nAs of March 1, 2026, there were approximately 96 holders of record of our common stock. A substantially greater number of holders of our common stock are “street name” or beneficial holders, whose shares are held of record by banks, brokers, and other financial institutions.\n\nDividend Policy\n\nTo date, we have not declared or paid any cash dividends on our common stock. We do not anticipate paying any dividends on our common stock in the foreseeable future.\n\n**Securities Authorized for Issuance under Equity Compensation Plans**\n\nThe following table provides information as of December 31, 2025 with respect to the shares of our common stock that may be issued under our existing equity compensation plan.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**  ​ ​ ​**\n\n**A**\n\n**  ​ ​ ​**\n\n**B**\n\n**  ​ ​ ​**\n\n**C**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Number of Securities Remaining**\n\n​\n\n​\n\n**Number of Securities**\n\n​\n\n​\n\n​\n\n​\n\n**Available for Future Issuance**\n\n​\n\n​\n\n**to be Issued**\n\n​\n\n**Weighted Average**\n\n​\n\n**Under Equity Compensation Plans**\n\n​\n\n​\n\n**Upon Exercise of**\n\n​\n\n**Exercise Price of**\n\n​\n\n**(Excluding Securities Reflected in**\n\n**Plan Category**\n\n​\n\n**Outstanding Options**\n\n​\n\n**Outstanding Options**\n\n​\n\n**Column A)**\n\nEquity Compensation Plans Approved by Stockholders\n\n \n\n8,274,278\n\n​\n\n$\n\n1.76\n\n \n\n2,092,933\n\nEquity Compensation Plans Not Approved by Stockholders\n\n \n\n-\n\n​\n\n \n\n-\n\n \n\n—\n\nTotal\n\n \n\n8,274,278\n\n​\n\n$\n\n1.76\n\n \n\n2,092,933\n\n​\n\nRecent Sales of Unregistered Securities\n\nNone.\n\nPurchases of Equity Securities by the Issuer and Affiliated Purchasers\n\nNone."}